PCM
TGTX icon

Penn Capital Management’s TG Therapeutics TGTX Stock Holding History

Penn Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5M Sell
536,067
-5,893
-1% -$241K 1.87% 5
2026
Q1 		$18M Buy
541,960
+3,843
+0.7% +$115K 1.4% 20
2025
Q4 		$16.1M Buy
538,117
+16,857
+3% +$551K 1.28% 29
2025
Q3 		$18.9M Buy
521,260
+77,895
+18% +$2.57M 1.45% 12
2025
Q2 		$16M Buy
443,365
+51,183
+13% +$1.91M 1.38% 26
2025
Q1 		$15.5M Buy
392,182
+40,774
+12% +$1.37M 1.51% 19
2024
Q4 		$10.6M Buy
+351,408
New +$10.1M 1.04% 52

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Penn Capital Management's TGTX Position: Q2 2026 in Review

Penn Capital Management reduced its TG Therapeutics (TGTX) stake by 1.1% in Q2 2026, selling an estimated $241K and leaving 536,067 shares worth $29.5M. The position accounts for 1.87% of the portfolio, ranked #5.

Penn Capital Management first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Penn Capital Management held 536,067 shares of TG Therapeutics worth $29.5M as of Q2 2026.
  • Penn Capital Management sold 5,893 TG Therapeutics shares in Q2 2026, an estimated $241K.
  • TG Therapeutics made up 1.87% of Penn Capital Management's portfolio in Q2 2026, its #5 holding.
  • Penn Capital Management first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Penn Capital Management's 13F filing for Q2 2026, filed 30 Jul 2026.